Taysha Gene Therapies (NASDAQ:TSHA) Issues Quarterly Earnings Results

Taysha Gene Therapies (NASDAQ:TSHA) announced its earnings results on Wednesday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.02), FiscalAI reports.

Here are the key takeaways from Taysha Gene Therapies’ conference call:

• Management said a Breakthrough Therapy Type B meeting with the FDA reaffirmed the BLA pathway and endpoints — including the option to pursue approval based on a 6?month interim analysis — and a BLA?enabling PPQ campaign started in April and is expected to complete by Q4 2026, with the FDA agreeing clinical and commercial material are comparable to allow data pooling.
• Dosing in the REVEAL pivotal and ASPIRE trials is on track to finish in Q2 2026, and Part A reported strong efficacy (high?dose response rates of 83% at 6 months and 100% at 9 months) with no treatment?related serious adverse events or dose?limiting toxicities as of the May cutoff.
• Preclinical data (to be presented at ASGCT) showed self?complementary AAV9 produces ~30?fold higher neuronal transduction versus single?stranded AAV9, miniMECP2 is functionally comparable to full?length MECP2, and NHP studies support lumbar intrathecal delivery as a minimally invasive, scalable CNS route.
• Taysha said it has assembled senior commercial leadership and is developing launch, payer, and health?systems strategies, with additional commercial plans to be shared in the second half of 2026.
• Operating spend rose sharply (R&D and G&A), widening the Q1 net loss to $42.4 million from $21.5 million a year earlier, although the company reported $276.6 million in cash, which it expects will fund operations into 2028.

Taysha Gene Therapies Stock Up 0.6%

Shares of NASDAQ TSHA traded up $0.04 during mid-day trading on Wednesday, reaching $6.98. The company had a trading volume of 3,125,981 shares, compared to its average volume of 2,750,156. Taysha Gene Therapies has a twelve month low of $1.85 and a twelve month high of $7.30. The company has a debt-to-equity ratio of 0.20, a quick ratio of 12.23 and a current ratio of 12.23. The stock has a market capitalization of $2.01 billion, a PE ratio of -20.57 and a beta of 1.25. The stock’s 50 day moving average is $4.99 and its 200-day moving average is $4.90.

Insider Buying and Selling at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 200,000 shares of the company’s stock in a transaction on Friday, April 10th. The shares were sold at an average price of $4.46, for a total value of $892,000.00. Following the completion of the sale, the insider directly owned 1,136,410 shares in the company, valued at approximately $5,068,388.60. This represents a 14.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.78% of the company’s stock.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of large investors have recently bought and sold shares of the business. Intech Investment Management LLC boosted its holdings in Taysha Gene Therapies by 3.6% in the fourth quarter. Intech Investment Management LLC now owns 71,069 shares of the company’s stock worth $391,000 after purchasing an additional 2,443 shares in the last quarter. Virtus Investment Advisers LLC boosted its holdings in Taysha Gene Therapies by 7.0% during the fourth quarter. Virtus Investment Advisers LLC now owns 45,946 shares of the company’s stock valued at $253,000 after acquiring an additional 3,008 shares during the period. Caitong International Asset Management Co. Ltd lifted its stake in shares of Taysha Gene Therapies by 143.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock valued at $43,000 after buying an additional 4,607 shares during the period. Legal & General Group Plc lifted its stake in shares of Taysha Gene Therapies by 25.8% in the third quarter. Legal & General Group Plc now owns 23,149 shares of the company’s stock valued at $76,000 after buying an additional 4,754 shares during the period. Finally, Cetera Investment Advisers lifted its stake in shares of Taysha Gene Therapies by 30.9% in the fourth quarter. Cetera Investment Advisers now owns 21,154 shares of the company’s stock valued at $116,000 after buying an additional 4,992 shares during the period. 77.70% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

TSHA has been the topic of several recent analyst reports. Truist Financial raised shares of Taysha Gene Therapies to a “strong-buy” rating in a research note on Wednesday, March 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Friday, March 27th. Canaccord Genuity Group boosted their target price on shares of Taysha Gene Therapies from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, April 6th. Wall Street Zen raised shares of Taysha Gene Therapies from a “sell” rating to a “hold” rating in a research note on Saturday, March 21st. Finally, Chardan Capital reissued a “buy” rating and set a $12.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, March 19th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $11.64.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.